Case IPR20] 7—01053
`
`Patent 8,268,299
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ARGENTUM PHARMACEUTICALS LLC
`
`Petitioner
`
`'V.
`
`ALCON RESEARCH, LTD
`Patent Owner
`
`Patent No. 8,268,299
`Issue Date: September 18, 2012
`Title: SELF PRESERVED AQUEOUS
`PHARMACEUTICAL COMPOSITIONS
`
`Inter Partes Review No. 2017-01053
`
`PATENT OWNER’S POWER OF ATTORNEY
`
`

`

`Case IPR 201 7-01053
`
`Patent 8,268,299
`
`Pursuant to 37 C.F.R. § 42.10(b), Alcon Research, Ltd., Patent Owner of
`
`US Patent No. 8,268,299, hereby appoints the following practitioners as its
`
`attorneys to transact all business in the Patent Trial & Appeal Board of the United
`
`States Patent and Trademark Office connected with the above-identified petition
`
`for inter partes review:
`
`David M. Krinsky (Reg. No. 72,339)
`Christopher A. Suarez (Reg. No. 72,553)
`WILLIAMS & CONNOLLY LLP
`
`725 Twelfth Street, NW.
`Washington, DC 20005
`Tel.: (202) 434—5000
`Fax: (202) 434-5029
`Email: dkrinsky@wc.com, csuarez@wc.corn
`
`The undersigned is authorized to Sign this Power of Attorney on behalf of Alcon
`Research, Ltd.
`
`Date: 28 March 2017
`
`
`
`

`

`Case [PR 2017-01053
`
`Parent 8,268, 299
`
`CERTIFICATE OF SERVICE
`
`[37 C.F.R. § 42.619.“
`
`The undersigned hereby certifies. that the foregoing document was served on
`
`March 28, 2017 by delivering a copy via electronic mail on the following attorneys
`
`of record for the Petitioner:
`
`Michael R. Houston, PhD. (Reg. No. 58,486)
`Joseph. P. Meara, .Ph.D. (Reg. No. 44,932)
`James P. McFarland, PhD. (Reg. No. 69,440)
`Tyler C. Liu (Reg. No.- 72,126)
`Foley &-Lardner LLP, 3000 K St. N.W., Suite 600
`Washington, DC. 20008
`ARG«travatanZ@foley.eom
`
`/David M. Krinst/
`David M. Krinsky
`Reg. No. 72.339
`Lead Counsel for Patent Owner
`
`Date: March 28, 2017
`
`

`

`at New at is
`
`Power of Attorney
`
`By this Power of Attorney, effective 01 _.lan.uary 201.7, Alco‘n Research, Ltd, a company
`incorpm'ated under the laws of the State of Delaware and having. its principal place of
`business at 6201- South Freeway, Fort Worth, TX 76134—2099 (“the Company”), hereby
`grants to the Novartis Group Companies listed below (“the Corporate- Signatorie§’):
`
`a)
`
`.b)
`
`c)
`
`the revocable authority to sign documents on behalf of the Company in
`connection with filing, prosecution, maintenance, and administration of any
`intellectual property right
`for
`copyright, design, domain
`name, patent,
`Supplementary protoction certificate (SPC) and trademark registration or any
`application therefore. standing in the name of the Company (“1P”);
`
`the revooable authority to sign. documents on behalf of the Company in
`connection with litigation relating to defense of 1? before a govormnen-tal
`authority; and
`
`the revocable anther-fly to sign Cm‘tftrmatory Assignments on behalf of the
`Company. “Confinnatory Assignments” are agreements between the Company
`and a third party or a Novartis Group entity that do not create new rights or
`obligations for the Company, such rights having been created by an underlying
`agreement (e.g. ocquisiti(Jo/divestment agreement, research funding/coilaboration
`agreement, and the like) and whet-eh}r the Contirrnatory Assignment merely
`executes the transfer of II’ as agreed in such underlying agreement;
`
`and for no other pmposes,
`
`This Power of Attorney excludes the power to cenclude contracts, other than
`Con‘firmatory Assignments, or to enter into settlements on behalf of the Company.
`The
`terms
`“contracts”
`and
`“settlements”
`include
`license
`agreements,
`acqu-isition/diVestinent agreements, assignments, prior right agreements and/or letters of
`consent.
`
`This Power of Attorney incindes the power to appoint external agents within the scope of '
`this Power of Attorney.
`
`To be. iegally binding upon the Company, alt relevant documents require the signature of
`two employees of one or more of the Corporate Signatofies as set out below (“Personal
`Signatories") who are authorized to sign for their respective CorpOr-ate Signatory, except
`where a single Personal Signatory is: permitted according to the. Novart-is internal
`“intellectual Property Signature Guidelines”.
`
`

`

`Corporate .Signato-r'ies-
`
`l’ersonal Signatorics
`
`Alcon Research, Ltd.
`
`Barbara McKenzie
`
`'C andy- Sanders;
`Christiaune K. Garrow
`
`Christine Bohmann
`'Darien L. Reddick
`
`Deborah Weinsohenk
`Denise C. Vivar
`
`Glenda Woife
`Janis M. Mendolia
`}213011 Finch
`
`Jian Zhou
`
`Joseph R. Weatherbee
`Keik-o Ichiye
`Kelly Bryant
`Kenneth D. Bassinger
`Lea Ann Rector
`
`Martha J. Martin
`Michael Rein
`
`Patrick M. Ryan
`Robert Ambrose
`
`Roxamm Hedger
`Russell E. Henrichs
`
`Matthew A. Hayenga
`Shelley Rose~30hn_son
`Sheng-Hsin H‘u
`Stephanie-J. Boyle:
`Steven Brannon 'Latimer
`Tamika Adams
`Vanessa Backman
`
`Yolanda 1. Sanchez
`
`Alcon S. A.
`
`John Ward
`
`Page 2 01‘3
`
`

`

`Carpal-ate Signator’ics
`
`Personal Signatories
`
`NOVfll‘tiS Pharmaceuticals Corporation
`
`Andrea Jacquin
`._Annelte (Emmet
`
`Cindy Klepacky
`Diane Leone
`
`Jason I. Derry
`Keliy Stri‘tenberger
`Lauren. Bosco
`Linda Adams
`Maria Stachura
`
`Mark E. Flanigan
`Scott A. Chapp'le
`Sherri Rose
`Sveflana 'KOI‘ZhiH
`
`This Power-of—Attomey 'is valid until 31 st December 201?? and supersedes as of its
`effective date all previous versions of Powers of Attorney relating to the subject matter
`herein.
`
`Fort Worth, 17 January 20}?
`.ALCON RESEARCI‘I, LTD.
`
`Christine Bah-mam”;
`
`Head Legal I]? and .AssiSIant Secretary
`
`Page 3 of 3
`
`